About: Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.50 (+5.22%)
ACTU NASDAQ Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. Common stock share price
Atividade de preço de ACTU
Último preço
$ 0,500
Variação (24h)
0,02 USD (5,22%)
Volume
73.87K
Volume (média 4 sem.)
-
Abertura
$ 0,51
Variação do dia
$ 0,48 - $ 0,51
Fechamento anterior
$ 0,48
Último negócio
26 Oct, 3:01 pm GMT+0
Atrasado
26 Oct, 3:01 pm GMT+0
ACTU price performance
Atrasado
26 Oct, 3:01 pm GMT+0
quote.marketSignals